Maria Shariat - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran. Stem Cell Technology Research Center, Tehran, Iran.
Shiva Irani - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Masoud Soleimani - Stem Cell Technology Research Center, Tehran, Iran.
Navid Goodarzi - Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran ۱۴۱۷۶۱۴۴۱۱, Iran
Rassoul Dinarvand - Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran ۱۴۱۷۶۱۴۴۱۱, Iran.Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

The functional significance of upregulation miR-34a in combination with albumin-bound paclitaxel nanoparticles in U251 glioblastoma cell line has been evaluated. The MTT assay determined that miR-34a and albumin-bound paclitaxel nanoparticles can reduce cell viability, but the combination of both factors has a stronger effect on cell viability. The application of qRT-PCR has demonstrated that the transduction of miR-34a could lead to exogenous upregulation of miR-34a level and downregulation of SURVIVIN. Moreover, treatment of U251 cells with miR-34a and nanoparticles together considerably inhibit SURVIVIN expression compared to miR-34a and nanoparticles alone. Flow cytometry showed that upon miR-34a overexpression cell cycle arrested in G1, while treatment with nanoparticles increased the cell population in G2 phase. Upregulation of miR-34a along with treatment with nanoparticles elevate the number if cells arrested in G1/ G2 phases of the cell cycle. Expression of miR-34a with albumin-bound paclitaxel nanoparticles reduce cell viability, downregulate SURVIVIN and enhance cell cycle arrest in G1/G2 phases and upregulation of miR-34a with these nanoparticles may be therapeutic for glioblastoma cancer.

miR-34a, glioblastoma, albumin, paclitaxel, nanoparticles, combination therapy.